Drug intelligence / Profile preview

fosinopril

Development stage
Approved
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension) and congestive heart failure in adults and children aged 6 years and older. It is a phosphinic acid-containing ester prodrug that is rapidly hydrolyzed in the body to its active metabolite, fosinoprilat. Fosinoprilat acts as a specific competitive inhibitor of ACE, blocking the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor involved in blood pressure regulation via the renin-angiotensin-aldosterone system (RAAS). By inhibiting ACE, fosinopril decreases levels of angiotensin II, leading to vasodilation, reduced aldosterone secretion, lower blood pressure, and decreased cardiac workload. This mechanism also helps slow progression of renal disease in hypertensive patients with diabetes mellitus.

Brand names
Monopril
Other names
fosinopril sodiumfosinoprilat
02

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on fosinopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fosinopril.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call